Through in-depth analysis, we identified and validated the protective effect of Solute Carrier Family 26 Member 4 (SLC26A4) in PCa, which may guide the application of poly(ADP-ribose) polymerase (PARP) inhibitors in PCa complementary to the commonly HRD-related gene mutations. The gene discussed is SLC26A4; the disease is posterior cortical atrophy.